Form 4: CPIX Director James Jones Boosts Stake via 10b5-1 Plan

Cumberland Pharmaceuticals Director James Jones acquired additional common stock through a pre-arranged 10b5-1 plan in August 2025.

Summary

• James Jones, a Director of Cumberland Pharmaceuticals Inc. (CPIX), acquired 262 shares of the company's common stock.
• The transactions occurred on multiple dates between August 1, 2025, and August 29, 2025.
• The purchase prices for the shares ranged from $2.84 to $4.01 per share.
• These acquisitions were executed automatically pursuant to a Rule 10b5-1 plan adopted by Mr. Jones on November 14, 2024.
• Following these transactions, James Jones directly owns a total of 43,938 shares of Cumberland Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The director's consistent, albeit small, purchases of company stock under a pre-arranged 10b5-1 plan indicate a sustained belief in the company's long-term value, though the pre-scheduled nature and modest size of transactions temper the immediate positive signal.

Positives

• A company director is increasing their beneficial ownership, which can signal confidence in the company's future prospects.
• The consistent purchases over several weeks, even in small increments, suggest a sustained belief in the company's long-term value.

Negatives

• The individual transaction sizes are very small (mostly 13 shares per day), which may limit the perceived significance of the insider buying.
• The purchases were made under a pre-arranged 10b5-1 plan, meaning they do not necessarily reflect new, immediate discretionary confidence based on recent non-public information.

Stakeholder Impact

• Shareholders may interpret the director's increased stake as a positive indicator of management's confidence in the company's future, potentially bolstering investor sentiment.

Key Dates

Recommendation

While a director's purchase of company stock is generally a positive signal, the transactions were executed under a pre-arranged 10b5-1 plan and involved relatively small amounts of shares. This suggests a consistent, long-term belief in the company rather than a reaction to new, immediate information. Therefore, it reinforces a 'hold' position for existing investors, but does not present a compelling new reason for a 'buy' or 'sell' recommendation.

Keywords

Cumberland Pharmaceuticals, CPIX, Insider Buying, Form 4, James Jones, Director, Stock Purchase, 10b5-1 Plan, Beneficial Ownership